%0 Journal Article
%T Management of Newly Diagnosed Multiple Myeloma Today, and in the Future.
%A Devasia AJ
%A Lancman GS
%A Stewart AK
%J Hematol Oncol Clin North Am
%V 38
%N 2
%D 2024 Apr 2
%M 38171937
%F 2.861
%R 10.1016/j.hoc.2023.12.007
%X Treatment options have expanded rapidly and widely in the past two decades for patients with multiple myeloma. Triplet novel agent-based induction regimens have been accepted as the standard practice wordwide over the last decade both for transplant-eligible and non-eligible patients. The addition of anti-CD38 monoclonal antibodies as part of quadruplet regimens has led to even deeper and longer-lasting responses. The impressive results shown by the quadruplets havebeen practice-changing where accessible in recent years. Chimeric antigen receptor T cell therapy and bispecific antibodies are being tested in the upfront setting and have the potential to once again shift the paradigm of treatment of newly diagnosed MM.